These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 28707500)

  • 1. Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy.
    Chatterjee S; Lesniak WG; Nimmagadda S
    Mol Imaging; 2017; 16():1536012117718459. PubMed ID: 28707500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?
    Verhoeff SR; van den Heuvel MM; van Herpen CML; Piet B; Aarntzen EHJG; Heskamp S
    PET Clin; 2020 Jan; 15(1):35-43. PubMed ID: 31735300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
    Aguiar PN; De Mello RA; Hall P; Tadokoro H; Lima Lopes G
    Immunotherapy; 2017 May; 9(6):499-506. PubMed ID: 28472902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
    Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
    Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
    Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
    Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G
    J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.
    Mu W; Jiang L; Shi Y; Tunali I; Gray JE; Katsoulakis E; Tian J; Gillies RJ; Schabath MB
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging biomarkers for PD-1 pathway cancer therapy.
    Lim JS; Sundar R; Chénard-Poirier M; Lopez J; Yap TA
    Biomark Med; 2017 Jan; 11(1):53-67. PubMed ID: 27936870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
    Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
    Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
    Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
    Liu D; Wang S; Bindeman W
    J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.